CCS adapting to COVID-19 realities to support Canadians during and after the pandemic
Dr Uri Tabori
Bernard and Francine Dorval Prize recipient in 2016
Dr Uri Tabori is a talented clinician-scientist who has quickly emerged as a world leader in pediatric oncology research and practice. His work has advanced the scientific community’s understanding of childhood brain tumours, especially in the context of children with cancer predisposition syndromes.
Among Dr Tabori’s outstanding contributions is his demonstration of the role of maintaining the ends of chromosomes (telomeres) in the biology of childhood brain tumours. Dr Tabori has also helped explain the molecular basis of pediatric low-grade gliomas (PLGGs), the most common brain tumours in children. He initiated a multidisciplinary Canadian low-grade glioma task force and maintains the largest database of clinical and pathological data on PLGG in the world. Another one of Dr Tabori’s large-scale initiatives was the establishment and leadership of an international consortium of researchers dedicated to studying biallelic mismatch repair deficiency (BMMRD) – a rare cancer predisposition syndrome – leading to a high-impact publication showing that brain cancers in children with BMMRD have more mutations than most cancer types. Overall, the foundational cancer research that Dr Tabori performs acts as a springboard to translate knowledge to clinical application.
Dr Tabori’s commitment to improving children’s health worldwide is evidenced by his outreach activities, including monthly telemedicine meetings with clinicians at children’s cancer centres in developing countries. Dr Tabori is a strong advocate for Canadian cancer research, generously volunteering his time and expertise to the Canadian Cancer Society and other funders as a grant reviewer and participant in fundraising activities. His outstanding potential has been recognized by prestigious early career awards, and his research is having a direct impact on cancer care.